Related Experiment Video
Updated: Dec 16, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Pulsed Levosimendan in advanced heart failure due to congenital heart disease: a case series
James Cranley1, Antonia Hardiman1, Leisa J Freeman1
1Cardiology Department, Norfolk and Norwich University Hospital, Colney Lane, Norwich NR4 7UY, UK.
Background:
Levosimendan is a non-adrenergic calcium-sensitizing agent with positive inotropic and vasodilatory effects. Its use in acute decompensation of heart failure is established. Good evidence now exists for repetitive infusions of Levosimendan to improve symptoms and reduce hospitalization in advanced heart failure (AdHF) populations. Its use in heart failure resulting from congenital heart disease is not yet commonplace.
Case Summary:
We present three cases in which pulsed Levosimendan was used in the management of AdHF secondary to underlying congenital heart disease. There was symptomatic and biomarker evidence of improvement.
Discussion:
Intermittent Levosimendan may represent a valuable therapy to reduce hospitalization and improve quality of life in adults with congenital heart conditions.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Mitral Stenosis III: Medical Management
Heart Failure V: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure III: Clinical Manifestations
Heart Failure II: Pathophysiology

